Dexrazoxane
- Generic Name
- Dexrazoxane
- Brand Names
- Savene, Totect, Zinecard
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 24584-09-6
- Unique Ingredient Identifier
- 048L81261F
- Background
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]
The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
- Indication
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
- Associated Conditions
- Doxorubicin Induced Cardiomyopathy, Drug Extravasation
Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo plus Mitoxantrone (MX)
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- PD Dr. Andrew Chan
- Target Recruit Count
- 50
- Registration Number
- NCT01627938
- Locations
- 🇩🇪
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
- Conditions
- Childhood Solid NeoplasmRecurrent NeuroblastomaRecurrent Childhood Anaplastic Large Cell Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyOther: Questionnaire Administration
- First Posted Date
- 2012-05-28
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 46
- Registration Number
- NCT01606878
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents
- Conditions
- Extravasations of Anthracycline Anti-cancer Agents
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT01596088
- Locations
- 🇯🇵
Japan, Tokyo and Other Japanese City, Japan
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT01523977
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸UCSF, San Francisco, California, United States
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
- Conditions
- OsteosarcomaLung Metastases
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT01258634
- Locations
- 🇺🇸
University of Chicago Department of Pediatrics Hematology/Oncology, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
- Conditions
- Peripheral Primitive Neuroectodermal Tumor of Soft TissuesPeripheral Primitive Neuroectodermal Tumor of BoneLocalized Extraskeletal Ewing Sarcoma
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 642
- Registration Number
- NCT01231906
- Locations
- 🇺🇸
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸Corewell Health Children's, Royal Oak, Michigan, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
- Conditions
- Cardiac ToxicityLeukemiaLymphoma
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 573
- Registration Number
- NCT01230983
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
- Conditions
- PRETEXT IV HepatoblastomaPRETEXT II HepatoblastomaPRETEXT III HepatoblastomaPRETEXT I Hepatoblastoma
- Interventions
- Procedure: Therapeutic Conventional SurgeryOther: Laboratory Biomarker AnalysisProcedure: Liver Transplantation
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 236
- Registration Number
- NCT00980460
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸C S Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸Albany Medical Center, Albany, New York, United States
Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 12
- Registration Number
- NCT00955890
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
- Conditions
- Acute Leukemias of Ambiguous LineageAcute Undifferentiated LeukemiaAngioimmunoblastic T-cell LymphomaBlastic Phase Chronic Myelogenous LeukemiaChildhood Burkitt LymphomaChildhood Chronic Myelogenous LeukemiaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaChildhood Nasal Type Extranodal NK/T-cell LymphomaCutaneous B-cell Non-Hodgkin Lymphoma
- Interventions
- Other: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00933985
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Indiana University Medical Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.